ClinicalTrials.gg
RecruitingNCT05339360Updated Nov 25, 2025

ZNN Bactiguard Antegrade Femoral Nails PMCF Study

An observational study in Femur Fracture and Osteotomy, sponsored by Zimmer Biomet. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Zimmer Biomet · Observational

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, prospective, Post-market Clinical Follow-up (PMCF) Study on the ZNN Bactiguard Antegrade Femoral Nails. The objective of this study is to collect data confirming the safety, performance, and clinical benefit of the study device and instrumentation when used for the temporary internal fixation and stabilization of femoral fractures and osteotomies.

This is a CE-marked device already available on the market and the aim of the study is to comply with the post-market surveillance requirements.

Read the detailed description

This study is a multicentre, prospective, post-market clinical follow-up study on the Zimmer Natural Nail (ZNN) Bactiguard Antegrade Femoral Nails.

The primary endpoint for this study is the assessment of performance by analyzing fracture healing within 12 months after fracture fixation. Fracture healing will be analyzed radiologically by the RUSH score adapted to the femur and clinically by the Fix-IT score.

The secondary endpoint is the assessment of safety, clinical benefit, and post-op fracture-related infection (FRI). Safety will be evaluated by recording and analyzing the incidence and frequency of complications and adverse events.

Relation of the events to implant, instrumentation and/or procedure should be specified. Clinical benefit will be assessed by recording patient-reported outcome measures (PROMs). FRIs will be classified according to the updated diagnostic algorithm defined by the FRI Consensus Group.

Data will be collected at 6 weeks, 3 months, 6 months and 1 year after fracture fixation.

The study will enroll patients implanted with the Zimmer Natural Nail Bactiguard Antegrade Femoral Nail according to the approved/cleared indications. The sample size for this study is 100 study cases, and up to 10 sites in EMEA will participate.

02

Conditions studied

  • Femur Fracture
  • Osteotomy

Browse trials for

Keywords

  • Intramedullary antegrade femoral nail
  • Bactiguard
03

In context

Femoral Fractures

187 studies on the registry are indexed under Femoral Fractures; 39 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 67 observational studies indexed under Femoral Fractures.

Browse Femoral Fractures studies →

Lead sponsor

Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Consecutive series of patients aged 18 or older with femur fractures or osteotomies implanted with the ZNN Bactiguard Antegrade Femoral Nail according to the approved/cleared indications.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be 18 or older
  • Patient must have a signed EC-approved .
  • Patient must have a femoral fracture (open, closed, monolateral, or bilateral) requiring surgical intervention or osteotomy and be eligible for fixation by intramedullary nailing. Patients with delayed treatment (initial treatment by external fixation due to swelling/ high energy trauma followed by definitive treatment by intramedullary nail) can also be included.
  • Patient has been or is scheduled to be treated with the ZNN Bactiguard System Antegrade Femoral Nail
  • Patient must be able and willing to complete the protocol required for follow-up
  • Patients capable of understanding the surgeon's explanations and following his instructions

Exclusion criteria

Exclusion Criteria:

Skeletally immature patients

  • Medullary canal obliterated by a previous fracture or tumor
  • Bone shaft having excessive bow or a deformity
  • Lack of bone substance or bone quality, which makes stable seating of the implant impossible
  • All concomitant diseases that can impair the operation, functioning or the success of the implant
  • Insufficient blood circulation
  • Infection
  • Patient is unwilling to give consent.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, subjects with alcohol/drug addiction, known to be pregnant or breast feeding)
  • Patient anticipated to be non-compliant and/or likely to have problems with maintaining follow-up program (e.g. patient with no fixed address, long-distance, plans to move during the course of study)
  • Patients not expected to survive the duration of the follow-up program
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • ZNN Bactiguard Antegrade Femoral Nail

    Subjects that have received or will receive the ZNN Bacitugard Antegrade Femoral Nail to treat femoral fractures or osteotomies according to the cleared/approved indications.

    Procedure: Femoral fixation with intramedullary nails

Interventions

  • ProcedureFemoral fixation with intramedullary nails

    Femoral fracture fixation Femoral Osteotomy

06

What researchers measure

Primary outcomes

  1. Performance of the study device

    Analyzed as fracture healing 12 months after fracture fixation. Fracture healing will be analyzed radiographically and clinically. Radiographic healing is considered achieved when two or more cortices reach a score of two (2) on a version of the Radiographic Union-Scale in Tibial fractures (RUST) tool adapted for the femur, in A/P and lateral views. Clinical fracture healing will be assessed via the FiX-IT score.

    Time frame: 12 months after fracture fixation

Secondary outcomes

  1. Safety assesment

    Recording and analyzing incidence and frequency of adverse events.

    Time frame: 6 weeks and 3, 6, and 12 months after fracture fixation

  2. Oxford Hip Score

    Patient-Reported Outcome Measures (PROMs) that documents hip function and pain. It's used as a surrogate to assess function and pain of the operated limb.

    Time frame: 3, 6, and 12 months after fracture fixation

  3. EQ-5D Health Questionnaire

    Patient-reported outcome completed by the patient. It assesses the general health status of the patient and it can be used to derive a quality of life index used for health economics considerations.

    Time frame: 3, 6, and 12 months after fracture fixation

  4. Rate of fracture-related infections

    Fracture-related infections are diagnosed in accordance with the algorithm described in M McNally, G Govaert, M Dudareva, M Morgenstern, W J Metsemakers, EFORT Open Rev 2020;5:614-619.

    Time frame: 6 weeks and 3, 6, and 12 months after fracture fixation

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2027, 36 months after the start.

Of 29 observational studies under Femoral Fractures, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2022
First posted
Apr 21, 2022
StartActual
Jan 16, 2024
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2027
Last update
Nov 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05339360
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Jan 16, 2024
Primary completion
Jan 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 25, 2025

Study contacts

Gemma de Ramon Francàs
Contact
gemma.deramonfrancas@zimmerbiomet.com
+41 79 377 11 96
Lisa To
Contact
lisa.to@zimmerbiomet.com
+32 479 97 05 43
Emilie Rohmer
study director · Zimmer Biomet

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion